# A Study to Evaluate the Appropriateness of the Voriconazole Dosing Regimen

> **NCT03760276** · PHASE1 · COMPLETED · sponsor: **Seoul National University Hospital** · enrollment: 11 (actual)

## Conditions studied

- Fungal Infection

## Interventions

- **DRUG:** Voriconazole Oral Product (Vfend®)

## Key facts

- **NCT ID:** NCT03760276
- **Lead sponsor:** Seoul National University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-08-20
- **Primary completion:** 2018-10-28
- **Final completion:** 2018-10-28
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2018-11-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03760276

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03760276, "A Study to Evaluate the Appropriateness of the Voriconazole Dosing Regimen". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03760276. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*